FOLH1 and cancer: Four antibodies targeting EGFR, CD25, PSMA, and PD-L1, all of which are targeting cancers, yet anti-CD25 can also target Treg cells and anti-PD-L1 can block immune checkpoint for further enhancing anticancer host immunity [5, 14], have progressed to the clinical application stage but many more are possible in the future.